nodes	percent_of_prediction	percent_of_DWPC	metapath
Pasireotide—SSTR3—G alpha (i) signalling events—HCAR2—psoriasis	0.00981	0.0349	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—HCAR2—psoriasis	0.0094	0.0335	CbGpPWpGaD
Pasireotide—SSTR5—G alpha (i) signalling events—HCAR2—psoriasis	0.00834	0.0297	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.0078	0.0278	CbGpPWpGaD
Pasireotide—SSTR2—G alpha (i) signalling events—HCAR2—psoriasis	0.0077	0.0274	CbGpPWpGaD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00748	0.0266	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00678	0.0242	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00663	0.0236	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00612	0.0218	CbGpPWpGaD
Pasireotide—SSTR3—Peptide ligand-binding receptors—CCL20—psoriasis	0.00604	0.0215	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—HCAR2—psoriasis	0.00594	0.0212	CbGpPWpGaD
Pasireotide—SSTR1—Peptide ligand-binding receptors—CCL20—psoriasis	0.00579	0.0206	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—HCAR2—psoriasis	0.00569	0.0203	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00555	0.0198	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—IL13—psoriasis	0.00535	0.0191	CbGpPWpGaD
Pasireotide—SSTR5—Peptide ligand-binding receptors—CCL20—psoriasis	0.00514	0.0183	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—CCL20—psoriasis	0.0051	0.0182	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—HCAR2—psoriasis	0.00505	0.018	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—CCL20—psoriasis	0.00489	0.0174	CbGpPWpGaD
Pasireotide—SSTR2—Peptide ligand-binding receptors—CCL20—psoriasis	0.00474	0.0169	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—HCAR2—psoriasis	0.00466	0.0166	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—IL13—psoriasis	0.00438	0.0156	CbGpPWpGaD
Pasireotide—SSTR5—G alpha (i) signalling events—CCL20—psoriasis	0.00433	0.0154	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00405	0.0144	CbGpPWpGaD
Pasireotide—SSTR2—G alpha (i) signalling events—CCL20—psoriasis	0.004	0.0142	CbGpPWpGaD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00388	0.0138	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00344	0.0123	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—HCAR2—psoriasis	0.00336	0.012	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—IL10—psoriasis	0.00335	0.0119	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—HCAR2—psoriasis	0.00322	0.0115	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00318	0.0113	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—CCL20—psoriasis	0.00309	0.011	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—HCAR2—psoriasis	0.00305	0.0109	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—CCL20—psoriasis	0.00296	0.0105	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—HCAR2—psoriasis	0.00292	0.0104	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—HCAR2—psoriasis	0.00285	0.0102	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—IL10—psoriasis	0.00274	0.00976	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—HCAR2—psoriasis	0.00263	0.00938	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—CCL20—psoriasis	0.00262	0.00934	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—HCAR2—psoriasis	0.00259	0.00923	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—CCL20—psoriasis	0.00242	0.00862	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—HCAR2—psoriasis	0.00239	0.00852	CbGpPWpGaD
Pasireotide—Oedema peripheral—Mycophenolic acid—psoriasis	0.00206	0.00286	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Acitretin—psoriasis	0.00206	0.00286	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Fluocinolone Acetonide—psoriasis	0.00205	0.00285	CcSEcCtD
Pasireotide—Insomnia—Acitretin—psoriasis	0.00204	0.00284	CcSEcCtD
Pasireotide—Dry skin—Prednisolone—psoriasis	0.00204	0.00284	CcSEcCtD
Pasireotide—Pruritus—Methoxsalen—psoriasis	0.00202	0.0028	CcSEcCtD
Pasireotide—Anaemia—Hydroxyurea—psoriasis	0.00201	0.00279	CcSEcCtD
Pasireotide—Abdominal pain—Calcitriol—psoriasis	0.00201	0.00279	CcSEcCtD
Pasireotide—Dry skin—Hydrocortisone—psoriasis	0.00199	0.00277	CcSEcCtD
Pasireotide—Abdominal pain upper—Hydrocortisone—psoriasis	0.00199	0.00276	CcSEcCtD
Pasireotide—Hypokalaemia—Hydrocortisone—psoriasis	0.00198	0.00275	CcSEcCtD
Pasireotide—Decreased appetite—Acitretin—psoriasis	0.00196	0.00273	CcSEcCtD
Pasireotide—Fatigue—Acitretin—psoriasis	0.00195	0.00271	CcSEcCtD
Pasireotide—Abdominal distension—Prednisolone—psoriasis	0.00194	0.00269	CcSEcCtD
Pasireotide—Constipation—Acitretin—psoriasis	0.00193	0.00269	CcSEcCtD
Pasireotide—Alanine aminotransferase increased—Hydrocortisone—psoriasis	0.00192	0.00267	CcSEcCtD
Pasireotide—Hyperglycaemia—Cyclosporine—psoriasis	0.00191	0.00265	CcSEcCtD
Pasireotide—Abdominal distension—Hydrocortisone—psoriasis	0.00189	0.00263	CcSEcCtD
Pasireotide—Dizziness—Methoxsalen—psoriasis	0.00188	0.00262	CcSEcCtD
Pasireotide—Hyperglycaemia—Mycophenolate mofetil—psoriasis	0.00186	0.00259	CcSEcCtD
Pasireotide—Diabetes mellitus—Prednisone—psoriasis	0.00186	0.00259	CcSEcCtD
Pasireotide—Alopecia—Mycophenolic acid—psoriasis	0.00185	0.00257	CcSEcCtD
Pasireotide—Gastrointestinal pain—Acitretin—psoriasis	0.00185	0.00257	CcSEcCtD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.00183	0.00652	CbGpPWpGaD
Pasireotide—Asthenia—Calcitriol—psoriasis	0.00182	0.00253	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—HCAR2—psoriasis	0.0018	0.00641	CbGpPWpGaD
Pasireotide—Pruritus—Calcitriol—psoriasis	0.0018	0.0025	CcSEcCtD
Pasireotide—Abdominal pain—Acitretin—psoriasis	0.00179	0.00248	CcSEcCtD
Pasireotide—Headache—Methoxsalen—psoriasis	0.00179	0.00248	CcSEcCtD
Pasireotide—Abdominal distension—Triamcinolone—psoriasis	0.00178	0.00248	CcSEcCtD
Pasireotide—Influenza—Triamcinolone—psoriasis	0.00177	0.00246	CcSEcCtD
Pasireotide—Back pain—Mycophenolic acid—psoriasis	0.00176	0.00245	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—CCL20—psoriasis	0.00174	0.00621	CbGpPWpGaD
Pasireotide—Diarrhoea—Calcitriol—psoriasis	0.00174	0.00242	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—HCAR2—psoriasis	0.00173	0.00615	CbGpPWpGaD
Pasireotide—Dry skin—Dexamethasone—psoriasis	0.0017	0.00237	CcSEcCtD
Pasireotide—Dry skin—Betamethasone—psoriasis	0.0017	0.00237	CcSEcCtD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—JUN—psoriasis	0.0017	0.00606	CbGpPWpGaD
Pasireotide—Nausea—Methoxsalen—psoriasis	0.00169	0.00235	CcSEcCtD
Pasireotide—Hypokalaemia—Dexamethasone—psoriasis	0.00169	0.00235	CcSEcCtD
Pasireotide—Hypokalaemia—Betamethasone—psoriasis	0.00169	0.00235	CcSEcCtD
Pasireotide—Anaemia—Mycophenolic acid—psoriasis	0.00168	0.00234	CcSEcCtD
Pasireotide—SSTR1—GPCR downstream signaling—CCL20—psoriasis	0.00167	0.00595	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.00164	0.00584	CbGpPWpGaD
Pasireotide—Vertigo—Mycophenolic acid—psoriasis	0.00164	0.00227	CcSEcCtD
Pasireotide—SSTR3—Peptide ligand-binding receptors—CXCL8—psoriasis	0.00163	0.00581	CbGpPWpGaD
Pasireotide—Oedema peripheral—Mycophenolate mofetil—psoriasis	0.00163	0.00226	CcSEcCtD
Pasireotide—Asthenia—Acitretin—psoriasis	0.00162	0.00225	CcSEcCtD
Pasireotide—Vomiting—Calcitriol—psoriasis	0.00162	0.00225	CcSEcCtD
Pasireotide—Pruritus—Acitretin—psoriasis	0.0016	0.00222	CcSEcCtD
Pasireotide—Pruritus—Fluocinolone Acetonide—psoriasis	0.00159	0.00222	CcSEcCtD
Pasireotide—Headache—Calcitriol—psoriasis	0.00159	0.00221	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—CCL20—psoriasis	0.00158	0.00564	CbGpPWpGaD
Pasireotide—Hypertension—Mycophenolic acid—psoriasis	0.00157	0.00219	CcSEcCtD
Pasireotide—SSTR1—Peptide ligand-binding receptors—CXCL8—psoriasis	0.00156	0.00557	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—TAGAP—psoriasis	0.00156	0.00556	CbGpPWpGaD
Pasireotide—Diabetes mellitus—Methotrexate—psoriasis	0.00155	0.00216	CcSEcCtD
Pasireotide—Arthralgia—Mycophenolic acid—psoriasis	0.00155	0.00216	CcSEcCtD
Pasireotide—Myalgia—Mycophenolic acid—psoriasis	0.00155	0.00216	CcSEcCtD
Pasireotide—Diarrhoea—Acitretin—psoriasis	0.00155	0.00215	CcSEcCtD
Pasireotide—Anxiety—Mycophenolic acid—psoriasis	0.00154	0.00215	CcSEcCtD
Pasireotide—Decreased appetite—Hydroxyurea—psoriasis	0.00154	0.00214	CcSEcCtD
Pasireotide—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00154	0.00214	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—HCAR2—psoriasis	0.00153	0.00545	CbGpPWpGaD
Pasireotide—Fatigue—Hydroxyurea—psoriasis	0.00153	0.00213	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—CCL20—psoriasis	0.00152	0.00541	CbGpPWpGaD
Pasireotide—Constipation—Hydroxyurea—psoriasis	0.00152	0.00211	CcSEcCtD
Pasireotide—Nausea—Calcitriol—psoriasis	0.00151	0.0021	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.0015	0.00534	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—TAGAP—psoriasis	0.0015	0.00533	CbGpPWpGaD
Pasireotide—Alopecia—Cyclosporine—psoriasis	0.0015	0.00208	CcSEcCtD
Pasireotide—Dizziness—Acitretin—psoriasis	0.00149	0.00208	CcSEcCtD
Pasireotide—Dizziness—Fluocinolone Acetonide—psoriasis	0.00149	0.00207	CcSEcCtD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.00149	0.0053	CbGpPWpGaD
Pasireotide—Dry skin—Prednisone—psoriasis	0.00148	0.00206	CcSEcCtD
Pasireotide—SSTR5—GPCR downstream signaling—CCL20—psoriasis	0.00148	0.00528	CbGpPWpGaD
Pasireotide—Hypokalaemia—Prednisone—psoriasis	0.00147	0.00205	CcSEcCtD
Pasireotide—Alopecia—Mycophenolate mofetil—psoriasis	0.00146	0.00203	CcSEcCtD
Pasireotide—Hyperglycaemia—Betamethasone—psoriasis	0.00145	0.00201	CcSEcCtD
Pasireotide—Hyperglycaemia—Dexamethasone—psoriasis	0.00145	0.00201	CcSEcCtD
Pasireotide—Vomiting—Acitretin—psoriasis	0.00144	0.002	CcSEcCtD
Pasireotide—Vomiting—Fluocinolone Acetonide—psoriasis	0.00143	0.00199	CcSEcCtD
Pasireotide—Alanine aminotransferase increased—Prednisone—psoriasis	0.00143	0.00198	CcSEcCtD
Pasireotide—Headache—Acitretin—psoriasis	0.00142	0.00197	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—HCAR2—psoriasis	0.00141	0.00503	CbGpPWpGaD
Pasireotide—Headache—Fluocinolone Acetonide—psoriasis	0.00141	0.00196	CcSEcCtD
Pasireotide—Abdominal distension—Prednisone—psoriasis	0.00141	0.00196	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—JUN—psoriasis	0.00139	0.00496	CbGpPWpGaD
Pasireotide—Back pain—Mycophenolate mofetil—psoriasis	0.00139	0.00193	CcSEcCtD
Pasireotide—Hypotension—Mycophenolic acid—psoriasis	0.00139	0.00193	CcSEcCtD
Pasireotide—SSTR5—Peptide ligand-binding receptors—CXCL8—psoriasis	0.00139	0.00494	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—CXCL8—psoriasis	0.00138	0.0049	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—CCL20—psoriasis	0.00137	0.00487	CbGpPWpGaD
Pasireotide—Anaemia—Cyclosporine—psoriasis	0.00136	0.00189	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.00135	0.00188	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—CCL20—psoriasis	0.00135	0.0048	CbGpPWpGaD
Pasireotide—Insomnia—Mycophenolic acid—psoriasis	0.00134	0.00187	CcSEcCtD
Pasireotide—Nausea—Acitretin—psoriasis	0.00134	0.00187	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.00134	0.00478	CbGpPWpGaD
Pasireotide—Nausea—Fluocinolone Acetonide—psoriasis	0.00134	0.00186	CcSEcCtD
Pasireotide—Anaemia—Mycophenolate mofetil—psoriasis	0.00133	0.00185	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—TAGAP—psoriasis	0.00133	0.00473	CbGpPWpGaD
Pasireotide—Vertigo—Cyclosporine—psoriasis	0.00132	0.00184	CcSEcCtD
Pasireotide—SSTR1—G alpha (i) signalling events—CXCL8—psoriasis	0.00132	0.0047	CbGpPWpGaD
Pasireotide—Decreased appetite—Mycophenolic acid—psoriasis	0.00129	0.0018	CcSEcCtD
Pasireotide—Vertigo—Mycophenolate mofetil—psoriasis	0.00129	0.00179	CcSEcCtD
Pasireotide—Fatigue—Mycophenolic acid—psoriasis	0.00128	0.00178	CcSEcCtD
Pasireotide—SSTR2—Peptide ligand-binding receptors—CXCL8—psoriasis	0.00128	0.00456	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—TNF—psoriasis	0.00127	0.00454	CbGpPWpGaD
Pasireotide—Asthenia—Hydroxyurea—psoriasis	0.00127	0.00177	CcSEcCtD
Pasireotide—Hypertension—Cyclosporine—psoriasis	0.00127	0.00177	CcSEcCtD
Pasireotide—Constipation—Mycophenolic acid—psoriasis	0.00127	0.00177	CcSEcCtD
Pasireotide—Hyperglycaemia—Prednisone—psoriasis	0.00126	0.00175	CcSEcCtD
Pasireotide—Arthralgia—Cyclosporine—psoriasis	0.00125	0.00174	CcSEcCtD
Pasireotide—Myalgia—Cyclosporine—psoriasis	0.00125	0.00174	CcSEcCtD
Pasireotide—Anxiety—Cyclosporine—psoriasis	0.00125	0.00174	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—CCL20—psoriasis	0.00124	0.00443	CbGpPWpGaD
Pasireotide—Hypertension—Mycophenolate mofetil—psoriasis	0.00124	0.00172	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—TAGAP—psoriasis	0.00123	0.00436	CbGpPWpGaD
Pasireotide—Myalgia—Mycophenolate mofetil—psoriasis	0.00122	0.0017	CcSEcCtD
Pasireotide—Arthralgia—Mycophenolate mofetil—psoriasis	0.00122	0.0017	CcSEcCtD
Pasireotide—Anxiety—Mycophenolate mofetil—psoriasis	0.00122	0.0017	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.00122	0.00434	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.00122	0.00169	CcSEcCtD
Pasireotide—Diarrhoea—Hydroxyurea—psoriasis	0.00121	0.00169	CcSEcCtD
Pasireotide—Vertigo—Prednisolone—psoriasis	0.0012	0.00167	CcSEcCtD
Pasireotide—Back pain—Triamcinolone—psoriasis	0.00119	0.00166	CcSEcCtD
Pasireotide—Vertigo—Hydrocortisone—psoriasis	0.00118	0.00164	CcSEcCtD
Pasireotide—Abdominal pain—Mycophenolic acid—psoriasis	0.00117	0.00163	CcSEcCtD
Pasireotide—Dizziness—Hydroxyurea—psoriasis	0.00117	0.00163	CcSEcCtD
Pasireotide—SSTR5—G alpha (i) signalling events—CXCL8—psoriasis	0.00117	0.00417	CbGpPWpGaD
Pasireotide—Hypertension—Prednisolone—psoriasis	0.00116	0.00161	CcSEcCtD
Pasireotide—Alopecia—Dexamethasone—psoriasis	0.00114	0.00158	CcSEcCtD
Pasireotide—Alopecia—Betamethasone—psoriasis	0.00114	0.00158	CcSEcCtD
Pasireotide—Hypertension—Hydrocortisone—psoriasis	0.00113	0.00157	CcSEcCtD
Pasireotide—Vomiting—Hydroxyurea—psoriasis	0.00113	0.00157	CcSEcCtD
Pasireotide—Myalgia—Hydrocortisone—psoriasis	0.00111	0.00155	CcSEcCtD
Pasireotide—Headache—Hydroxyurea—psoriasis	0.00111	0.00155	CcSEcCtD
Pasireotide—Anxiety—Hydrocortisone—psoriasis	0.00111	0.00154	CcSEcCtD
Pasireotide—Vertigo—Triamcinolone—psoriasis	0.00111	0.00154	CcSEcCtD
Pasireotide—Hypotension—Mycophenolate mofetil—psoriasis	0.0011	0.00152	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.0011	0.00152	CcSEcCtD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.00109	0.0039	CbGpPWpGaD
Pasireotide—Insomnia—Cyclosporine—psoriasis	0.00109	0.00151	CcSEcCtD
Pasireotide—SSTR2—G alpha (i) signalling events—CXCL8—psoriasis	0.00108	0.00385	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.00107	0.00149	CcSEcCtD
Pasireotide—Asthenia—Mycophenolic acid—psoriasis	0.00107	0.00148	CcSEcCtD
Pasireotide—Hypertension—Triamcinolone—psoriasis	0.00106	0.00148	CcSEcCtD
Pasireotide—Insomnia—Mycophenolate mofetil—psoriasis	0.00106	0.00147	CcSEcCtD
Pasireotide—Nausea—Hydroxyurea—psoriasis	0.00105	0.00147	CcSEcCtD
Pasireotide—Pruritus—Mycophenolic acid—psoriasis	0.00105	0.00146	CcSEcCtD
Pasireotide—Myalgia—Triamcinolone—psoriasis	0.00105	0.00146	CcSEcCtD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.00105	0.00374	CbGpPWpGaD
Pasireotide—Decreased appetite—Cyclosporine—psoriasis	0.00105	0.00145	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—TNF—psoriasis	0.00104	0.00372	CbGpPWpGaD
Pasireotide—Fatigue—Cyclosporine—psoriasis	0.00104	0.00144	CcSEcCtD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—IL6—psoriasis	0.00103	0.00366	CbGpPWpGaD
Pasireotide—Constipation—Cyclosporine—psoriasis	0.00103	0.00143	CcSEcCtD
Pasireotide—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00102	0.00142	CcSEcCtD
Pasireotide—Diarrhoea—Mycophenolic acid—psoriasis	0.00102	0.00141	CcSEcCtD
Pasireotide—Vertigo—Dexamethasone—psoriasis	0.001	0.0014	CcSEcCtD
Pasireotide—Vertigo—Betamethasone—psoriasis	0.001	0.0014	CcSEcCtD
Pasireotide—Constipation—Mycophenolate mofetil—psoriasis	0.001	0.00139	CcSEcCtD
Pasireotide—Hypotension—Hydrocortisone—psoriasis	0.000998	0.00139	CcSEcCtD
Pasireotide—Insomnia—Prednisolone—psoriasis	0.000989	0.00138	CcSEcCtD
Pasireotide—Alopecia—Prednisone—psoriasis	0.000989	0.00137	CcSEcCtD
Pasireotide—Gastrointestinal pain—Cyclosporine—psoriasis	0.000983	0.00137	CcSEcCtD
Pasireotide—Dizziness—Mycophenolic acid—psoriasis	0.000983	0.00137	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000973	0.00135	CcSEcCtD
Pasireotide—Insomnia—Hydrocortisone—psoriasis	0.000966	0.00134	CcSEcCtD
Pasireotide—Hypertension—Betamethasone—psoriasis	0.000966	0.00134	CcSEcCtD
Pasireotide—Hypertension—Dexamethasone—psoriasis	0.000966	0.00134	CcSEcCtD
Pasireotide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000959	0.00133	CcSEcCtD
Pasireotide—Myalgia—Dexamethasone—psoriasis	0.000952	0.00132	CcSEcCtD
Pasireotide—Myalgia—Betamethasone—psoriasis	0.000952	0.00132	CcSEcCtD
Pasireotide—Abdominal pain—Cyclosporine—psoriasis	0.00095	0.00132	CcSEcCtD
Pasireotide—Anxiety—Betamethasone—psoriasis	0.000949	0.00132	CcSEcCtD
Pasireotide—Anxiety—Dexamethasone—psoriasis	0.000949	0.00132	CcSEcCtD
Pasireotide—Vomiting—Mycophenolic acid—psoriasis	0.000945	0.00131	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—CCL20—psoriasis	0.000935	0.00333	CbGpPWpGaD
Pasireotide—Headache—Mycophenolic acid—psoriasis	0.000931	0.00129	CcSEcCtD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.00093	0.00331	CbGpPWpGaD
Pasireotide—Decreased appetite—Hydrocortisone—psoriasis	0.000929	0.00129	CcSEcCtD
Pasireotide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000927	0.00129	CcSEcCtD
Pasireotide—Fatigue—Hydrocortisone—psoriasis	0.000921	0.00128	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000917	0.00127	CcSEcCtD
Pasireotide—Insomnia—Triamcinolone—psoriasis	0.00091	0.00127	CcSEcCtD
Pasireotide—Anaemia—Prednisone—psoriasis	0.0009	0.00125	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—CCL20—psoriasis	0.000897	0.00319	CbGpPWpGaD
Pasireotide—Nausea—Mycophenolic acid—psoriasis	0.000883	0.00123	CcSEcCtD
Pasireotide—Vertigo—Prednisone—psoriasis	0.000875	0.00122	CcSEcCtD
Pasireotide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000874	0.00121	CcSEcCtD
Pasireotide—Fatigue—Triamcinolone—psoriasis	0.000867	0.00121	CcSEcCtD
Pasireotide—Asthenia—Cyclosporine—psoriasis	0.000863	0.0012	CcSEcCtD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000858	0.00306	CbGpPWpGaD
Pasireotide—Hypotension—Dexamethasone—psoriasis	0.000853	0.00119	CcSEcCtD
Pasireotide—Hypotension—Betamethasone—psoriasis	0.000853	0.00119	CcSEcCtD
Pasireotide—Pruritus—Cyclosporine—psoriasis	0.000851	0.00118	CcSEcCtD
Pasireotide—Abdominal pain—Hydrocortisone—psoriasis	0.000845	0.00117	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—IL6—psoriasis	0.000842	0.003	CbGpPWpGaD
Pasireotide—Asthenia—Mycophenolate mofetil—psoriasis	0.000841	0.00117	CcSEcCtD
Pasireotide—Hypertension—Prednisone—psoriasis	0.000841	0.00117	CcSEcCtD
Pasireotide—SSTR3—GPCR ligand binding—CXCL8—psoriasis	0.000833	0.00297	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000832	0.00116	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000832	0.00116	CcSEcCtD
Pasireotide—Pruritus—Mycophenolate mofetil—psoriasis	0.00083	0.00115	CcSEcCtD
Pasireotide—Myalgia—Prednisone—psoriasis	0.000829	0.00115	CcSEcCtD
Pasireotide—Arthralgia—Prednisone—psoriasis	0.000829	0.00115	CcSEcCtD
Pasireotide—Anxiety—Prednisone—psoriasis	0.000826	0.00115	CcSEcCtD
Pasireotide—Alopecia—Methotrexate—psoriasis	0.000826	0.00115	CcSEcCtD
Pasireotide—Insomnia—Betamethasone—psoriasis	0.000826	0.00115	CcSEcCtD
Pasireotide—Insomnia—Dexamethasone—psoriasis	0.000826	0.00115	CcSEcCtD
Pasireotide—Diarrhoea—Cyclosporine—psoriasis	0.000823	0.00114	CcSEcCtD
Pasireotide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000802	0.00112	CcSEcCtD
Pasireotide—SSTR1—GPCR ligand binding—CXCL8—psoriasis	0.000799	0.00285	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CCL20—psoriasis	0.000795	0.00283	CbGpPWpGaD
Pasireotide—Dizziness—Cyclosporine—psoriasis	0.000795	0.00111	CcSEcCtD
Pasireotide—Decreased appetite—Betamethasone—psoriasis	0.000794	0.0011	CcSEcCtD
Pasireotide—Decreased appetite—Dexamethasone—psoriasis	0.000794	0.0011	CcSEcCtD
Pasireotide—Back pain—Methotrexate—psoriasis	0.000787	0.00109	CcSEcCtD
Pasireotide—Fatigue—Dexamethasone—psoriasis	0.000787	0.00109	CcSEcCtD
Pasireotide—Fatigue—Betamethasone—psoriasis	0.000787	0.00109	CcSEcCtD
Pasireotide—Dizziness—Mycophenolate mofetil—psoriasis	0.000776	0.00108	CcSEcCtD
Pasireotide—Asthenia—Hydrocortisone—psoriasis	0.000767	0.00107	CcSEcCtD
Pasireotide—Vomiting—Cyclosporine—psoriasis	0.000764	0.00106	CcSEcCtD
Pasireotide—Pruritus—Hydrocortisone—psoriasis	0.000756	0.00105	CcSEcCtD
Pasireotide—Headache—Cyclosporine—psoriasis	0.000753	0.00105	CcSEcCtD
Pasireotide—Anaemia—Methotrexate—psoriasis	0.000752	0.00105	CcSEcCtD
Pasireotide—Gastrointestinal pain—Betamethasone—psoriasis	0.000746	0.00104	CcSEcCtD
Pasireotide—Gastrointestinal pain—Dexamethasone—psoriasis	0.000746	0.00104	CcSEcCtD
Pasireotide—Vomiting—Mycophenolate mofetil—psoriasis	0.000746	0.00104	CcSEcCtD
Pasireotide—Headache—Mycophenolate mofetil—psoriasis	0.000735	0.00102	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—CCL20—psoriasis	0.000734	0.00261	CbGpPWpGaD
Pasireotide—Vertigo—Methotrexate—psoriasis	0.000731	0.00102	CcSEcCtD
Pasireotide—Diarrhoea—Hydrocortisone—psoriasis	0.000731	0.00102	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Prednisone—psoriasis	0.000724	0.00101	CcSEcCtD
Pasireotide—Dizziness—Prednisolone—psoriasis	0.000723	0.00101	CcSEcCtD
Pasireotide—Asthenia—Triamcinolone—psoriasis	0.000722	0.001	CcSEcCtD
Pasireotide—Abdominal pain—Betamethasone—psoriasis	0.000722	0.001	CcSEcCtD
Pasireotide—Abdominal pain—Dexamethasone—psoriasis	0.000722	0.001	CcSEcCtD
Pasireotide—Insomnia—Prednisone—psoriasis	0.000719	0.001	CcSEcCtD
Pasireotide—Nausea—Cyclosporine—psoriasis	0.000714	0.000993	CcSEcCtD
Pasireotide—Pruritus—Triamcinolone—psoriasis	0.000712	0.00099	CcSEcCtD
Pasireotide—SSTR5—GPCR ligand binding—CXCL8—psoriasis	0.000708	0.00252	CbGpPWpGaD
Pasireotide—Dizziness—Hydrocortisone—psoriasis	0.000707	0.000982	CcSEcCtD
Pasireotide—Nausea—Mycophenolate mofetil—psoriasis	0.000697	0.000969	CcSEcCtD
Pasireotide—Myalgia—Methotrexate—psoriasis	0.000693	0.000964	CcSEcCtD
Pasireotide—Arthralgia—Methotrexate—psoriasis	0.000693	0.000964	CcSEcCtD
Pasireotide—Decreased appetite—Prednisone—psoriasis	0.000691	0.000961	CcSEcCtD
Pasireotide—Fatigue—Prednisone—psoriasis	0.000685	0.000953	CcSEcCtD
Pasireotide—Headache—Prednisolone—psoriasis	0.000685	0.000953	CcSEcCtD
Pasireotide—Constipation—Prednisone—psoriasis	0.00068	0.000945	CcSEcCtD
Pasireotide—Vomiting—Hydrocortisone—psoriasis	0.000679	0.000944	CcSEcCtD
Pasireotide—Headache—Hydrocortisone—psoriasis	0.000669	0.000931	CcSEcCtD
Pasireotide—Dizziness—Triamcinolone—psoriasis	0.000665	0.000925	CcSEcCtD
Pasireotide—Asthenia—Betamethasone—psoriasis	0.000655	0.000911	CcSEcCtD
Pasireotide—Asthenia—Dexamethasone—psoriasis	0.000655	0.000911	CcSEcCtD
Pasireotide—SSTR2—GPCR ligand binding—CXCL8—psoriasis	0.000654	0.00233	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Prednisone—psoriasis	0.00065	0.000904	CcSEcCtD
Pasireotide—Nausea—Prednisolone—psoriasis	0.00065	0.000903	CcSEcCtD
Pasireotide—Pruritus—Betamethasone—psoriasis	0.000646	0.000898	CcSEcCtD
Pasireotide—Pruritus—Dexamethasone—psoriasis	0.000646	0.000898	CcSEcCtD
Pasireotide—Vomiting—Triamcinolone—psoriasis	0.00064	0.000889	CcSEcCtD
Pasireotide—Nausea—Hydrocortisone—psoriasis	0.000635	0.000882	CcSEcCtD
Pasireotide—Headache—Triamcinolone—psoriasis	0.00063	0.000876	CcSEcCtD
Pasireotide—Abdominal pain—Prednisone—psoriasis	0.000628	0.000874	CcSEcCtD
Pasireotide—Diarrhoea—Dexamethasone—psoriasis	0.000625	0.000868	CcSEcCtD
Pasireotide—Diarrhoea—Betamethasone—psoriasis	0.000625	0.000868	CcSEcCtD
Pasireotide—Hypotension—Methotrexate—psoriasis	0.000621	0.000863	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000605	0.000842	CcSEcCtD
Pasireotide—Dizziness—Dexamethasone—psoriasis	0.000604	0.000839	CcSEcCtD
Pasireotide—Dizziness—Betamethasone—psoriasis	0.000604	0.000839	CcSEcCtD
Pasireotide—Insomnia—Methotrexate—psoriasis	0.000601	0.000835	CcSEcCtD
Pasireotide—Nausea—Triamcinolone—psoriasis	0.000598	0.000831	CcSEcCtD
Pasireotide—Vomiting—Betamethasone—psoriasis	0.00058	0.000807	CcSEcCtD
Pasireotide—Vomiting—Dexamethasone—psoriasis	0.00058	0.000807	CcSEcCtD
Pasireotide—Decreased appetite—Methotrexate—psoriasis	0.000578	0.000803	CcSEcCtD
Pasireotide—Fatigue—Methotrexate—psoriasis	0.000573	0.000796	CcSEcCtD
Pasireotide—Headache—Dexamethasone—psoriasis	0.000572	0.000795	CcSEcCtD
Pasireotide—Headache—Betamethasone—psoriasis	0.000572	0.000795	CcSEcCtD
Pasireotide—Asthenia—Prednisone—psoriasis	0.00057	0.000793	CcSEcCtD
Pasireotide—Pruritus—Prednisone—psoriasis	0.000562	0.000782	CcSEcCtD
Pasireotide—Diarrhoea—Prednisone—psoriasis	0.000544	0.000756	CcSEcCtD
Pasireotide—Gastrointestinal pain—Methotrexate—psoriasis	0.000543	0.000755	CcSEcCtD
Pasireotide—Nausea—Dexamethasone—psoriasis	0.000542	0.000754	CcSEcCtD
Pasireotide—Nausea—Betamethasone—psoriasis	0.000542	0.000754	CcSEcCtD
Pasireotide—Dizziness—Prednisone—psoriasis	0.000526	0.000731	CcSEcCtD
Pasireotide—Abdominal pain—Methotrexate—psoriasis	0.000525	0.00073	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—SOCS1—psoriasis	0.000515	0.00183	CbGpPWpGaD
Pasireotide—Vomiting—Prednisone—psoriasis	0.000505	0.000703	CcSEcCtD
Pasireotide—Headache—Prednisone—psoriasis	0.000498	0.000692	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—SOCS1—psoriasis	0.000494	0.00176	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—TYK2—psoriasis	0.000491	0.00175	CbGpPWpGaD
Pasireotide—Asthenia—Methotrexate—psoriasis	0.000477	0.000663	CcSEcCtD
Pasireotide—Nausea—Prednisone—psoriasis	0.000472	0.000657	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—CXCL8—psoriasis	0.000471	0.00168	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—TYK2—psoriasis	0.000471	0.00168	CbGpPWpGaD
Pasireotide—Pruritus—Methotrexate—psoriasis	0.00047	0.000654	CcSEcCtD
Pasireotide—Diarrhoea—Methotrexate—psoriasis	0.000455	0.000632	CcSEcCtD
Pasireotide—SSTR1—GPCR downstream signaling—CXCL8—psoriasis	0.000451	0.00161	CbGpPWpGaD
Pasireotide—Dizziness—Methotrexate—psoriasis	0.000439	0.000611	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—SOCS1—psoriasis	0.000438	0.00156	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—CXCL8—psoriasis	0.000428	0.00152	CbGpPWpGaD
Pasireotide—Vomiting—Methotrexate—psoriasis	0.000422	0.000587	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—TYK2—psoriasis	0.000418	0.00149	CbGpPWpGaD
Pasireotide—Headache—Methotrexate—psoriasis	0.000416	0.000579	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—CXCL8—psoriasis	0.00041	0.00146	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—SOCS1—psoriasis	0.000404	0.00144	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—CXCL8—psoriasis	0.0004	0.00143	CbGpPWpGaD
Pasireotide—Nausea—Methotrexate—psoriasis	0.000395	0.000549	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—TYK2—psoriasis	0.000385	0.00137	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—LEP—psoriasis	0.00038	0.00135	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—APOE—psoriasis	0.00038	0.00135	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—CXCL8—psoriasis	0.000369	0.00132	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—LEP—psoriasis	0.000364	0.0013	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—APOE—psoriasis	0.000364	0.0013	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CXCL8—psoriasis	0.000364	0.00129	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—NFKBIA—psoriasis	0.000354	0.00126	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—NFKBIA—psoriasis	0.00034	0.00121	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CXCL8—psoriasis	0.000335	0.0012	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—APOE—psoriasis	0.000323	0.00115	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—LEP—psoriasis	0.000323	0.00115	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—NFKBIA—psoriasis	0.000301	0.00107	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—LEP—psoriasis	0.000298	0.00106	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—APOE—psoriasis	0.000298	0.00106	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—TYK2—psoriasis	0.00029	0.00103	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—TYK2—psoriasis	0.000278	0.000991	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—NFKBIA—psoriasis	0.000278	0.00099	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CXCL8—psoriasis	0.000253	0.0009	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—TYK2—psoriasis	0.000247	0.000879	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CXCL8—psoriasis	0.000242	0.000863	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—IL6—psoriasis	0.00024	0.000855	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—JUN—psoriasis	0.000235	0.000836	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—IL6—psoriasis	0.00023	0.00082	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—TYK2—psoriasis	0.000228	0.000811	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—NFKB1—psoriasis	0.000226	0.000805	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—JUN—psoriasis	0.000225	0.000802	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—NFKB1—psoriasis	0.000217	0.000772	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CXCL8—psoriasis	0.000215	0.000765	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—VEGFA—psoriasis	0.000205	0.000731	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—IL6—psoriasis	0.000204	0.000727	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—STAT3—psoriasis	0.000203	0.000724	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—JUN—psoriasis	0.0002	0.000711	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CXCL8—psoriasis	0.000198	0.000706	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—VEGFA—psoriasis	0.000197	0.000701	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—STAT3—psoriasis	0.000195	0.000694	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—NFKB1—psoriasis	0.000192	0.000685	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—IL6—psoriasis	0.000188	0.000671	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—JUN—psoriasis	0.000184	0.000656	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—NFKB1—psoriasis	0.000177	0.000632	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—VEGFA—psoriasis	0.000174	0.000621	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—STAT3—psoriasis	0.000173	0.000615	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—VEGFA—psoriasis	0.000161	0.000573	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—STAT3—psoriasis	0.000159	0.000568	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—TP53—psoriasis	0.000155	0.000552	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—TP53—psoriasis	0.000149	0.000529	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—IL6—psoriasis	0.000142	0.000505	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—IL6—psoriasis	0.000136	0.000485	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—TP53—psoriasis	0.000132	0.000469	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—TP53—psoriasis	0.000122	0.000433	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—IL6—psoriasis	0.000121	0.00043	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—IL6—psoriasis	0.000111	0.000397	CbGpPWpGaD
